CommercialCoverageMedium impact
Ribavirin for Inhalation Use (CPB 0155, reviewed 2026-04-21)
Aetna·Pediatrics, Critical Care, Infectious Disease +2 more·Medical Policy
Effective date
Apr 21, 2026
We identified it
Aug 16, 2026
Summary
Aetna's updated CPB 0155 (effective 2026-04-21) clarifies that ribavirin for inhalation is covered ONLY for hospitalized infants and young children with severe RSV lower respiratory tract infections. All other indications (COVID-19, parainfluenza, malignancies, hepatitis E, etc.) are explicitly classified as experimental/investigational and not covered. Billing teams must deny claims for off-label uses and verify RSV diagnosis with appropriate ICD-10 codes before processing.
Action Required
By 2026-04-21, billing team must: (1) Update billing software to require ICD-10 diagnosis verification for ribavirin claims—ONLY allow CPT 90378 when paired with B97.4, J12.1, J20.5, or J21.0 (RSV diagnoses). (2) Configure system to AUTO-DENY or flag for manual review any ribavirin claims with excluded ICD-10 codes (J12.82 for COVID-19, J12.2 for parainfluenza, C73 for thyroid cancer, U07.1 for COVID-19, G35.A-G35.D for MS, etc.). (3) Add edit rules to deny claims if patient age is >18 years (ribavirin not indicated for adults). (4) Train billing staff and providers that ribavirin inhalation is experimental/investigational for all non-RSV severe LRTI cases and will be denied. (5) Do NOT bill ribavirin for cationic liposome encapsulated spray formulation. Failure to implement restrictions will result in claim denials and potential overpayment recovery.